Strong Independent Association of TILs with OS for Patients with ERBB2-positive Early Breast Cancer By Ogkologos - February 26, 2025 607 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from updated analysis of the ShortHER study Source RELATED ARTICLESMORE FROM AUTHOR Lisocabtagene Maraleucel Shows Deep, Durable Responses in Patients with Relapsed or Refractory MZL After at Least Two Previous Lines of Systemic Therapy FDA Updates Safety Labelling for Capecitabine and 5-FU on Risks Associated with DPD Deficiency Ultra-Low-Dose Nivolumab Significantly Improves OS Over Chemotherapy in Pretreated Patients with Solid Tumours MOST POPULAR Cancer Immunotherapy Drug Simultaneously Targets Two Proteins that Block Immune Response April 4, 2018 FDA Grants Accelerated Approval to Tafasitamab-cxix for DLBCL August 7, 2020 Longer Follow-Up Continues to Support First-Line Pembrolizumab Plus Chemotherapy in Metastatic... March 25, 2021 How to Spend Time with Friends and Family Now that COVID... August 13, 2020 Load more HOT NEWS Colposcopia: Cómo prepararse y qué saber Neoadjuvant Nivolumab Plus Chemotherapy Results in Significantly Longer Event-Free Survival in... Talk Cancer: How to have conversations that could save lives The director’s cut: How Dr Catherine Elliott sees the future of...
